Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma

Patients with pancreatic ductal adenocarcinoma (PDAC) have a grim prognosis despite complete surgical resection and intense systemic therapies. While immunotherapies have been beneficial with many different types of solid tumors, they have almost uniformly failed in the treatment of PDAC. Understand...

Descripción completa

Detalles Bibliográficos
Autores principales: Gartrell, Robyn D., Enzler, Thomas, Kim, Pan S., Fullerton, Benjamin T., Fazlollahi, Ladan, Chen, Andrew X., Minns, Hanna E., Perni, Subha, Weisberg, Stuart P., Rizk, Emanuelle M., Wang, Samuel, Oh, Eun Jeong, Guo, Xinzheng V., Chiuzan, Codruta, Manji, Gulam A., Bates, Susan E., Chabot, John, Schrope, Beth, Kluger, Michael, Emond, Jean, Rabadán, Raul, Farber, Donna, Remotti, Helen E., Horowitz, David P., Saenger, Yvonne M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090285/
https://www.ncbi.nlm.nih.gov/pubmed/35558160
http://dx.doi.org/10.1080/2162402X.2022.2066767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090285/
https://www.ncbi.nlm.nih.gov/pubmed/35558160
http://dx.doi.org/10.1080/2162402X.2022.2066767

Ejemplares similares